Brazilin from Caesalpinia sappan L. as a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Pharmacophore-Based Virtual Screening, In Silico Molecular Docking, and In Vitro Studies
Background. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial regulator of low-density lipoprotein cholesterol (LDL-c) levels, as it binds to and degrades the LDL receptor (LDLR) in the lysosome of hepatocytes. Elevated levels of PCSK9 have been linked to an increased LDL-c plasma l...
Saved in:
| Main Authors: | Muhammad Iqbal, Nur Hasanah, Aimee Detria Arianto, Widya Dwi Aryati, Meidi Utami Puteri, Fadlina Chany Saputri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Advances in Pharmacological and Pharmaceutical Sciences |
| Online Access: | http://dx.doi.org/10.1155/2023/5932315 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01) -
THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
by: Алексей Михайлович Чаулин, et al.
Published: (2019-12-01) -
Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01) -
The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
by: Natalie Schellack, et al.
Published: (2016-01-01) -
Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors
by: Je-Wen Liou, et al.
Published: (2024-09-01)